Dewpoint Receives FDA Orphan Drug Designation for DPTX3186
Dewpoint Therapeutics has received the US FDA's Orphan Drug Designation (ODD) for DPTX3186, a small-molecule condensate modulator for treating gastric cancer.
The ODD program incentivizes the development of medicines for conditions affecting fewer than 200,000 individuals in the US.
Dewpoint Therapeutics recently opened its Investigational New Drug application for the oral therapy, marking its entry as a clinical-stage biotech and the beginning of the first human trial involving a condensate-modulating therapeutic.
The gold standard of business intelligence.
Author's summary: Dewpoint receives FDA orphan drug designation.
More News
- Animal Crossing: New Horizons Gets a Free Update and Switch 2 Edition
- The myth of a straight Starmer v Farage choice exposed
- Better than Vlahovic? Barcelona set sights on incredible €75m new striker target
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- Barcelona edge Man City, Man Utd as LaLiga striker's stunning transfer options ranked
- Animal Crossing: New Horizons Getting Switch 2 Edition and Free Content Update
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- NewJeans loses Ador court battle to leave agency
- Nordic-Baltic regional unity is our biggest advantage - Vucans
- Eala falls to Mboko to exit Hong Kong Open